70 related articles for article (PubMed ID: 33766159)
1. Practical Aspects of Transitioning from Intravenous to Subcutaneous Immunoglobulin Therapy in Neuromuscular Disorders.
Menon D; Sarpong E; Bril V
Can J Neurol Sci; 2022 Mar; 49(2):161-167. PubMed ID: 33766159
[TBL] [Abstract][Full Text] [Related]
2. Effects of Body Mass and Age on the Pharmacokinetics of Subcutaneous or Hyaluronidase-facilitated Subcutaneous Immunoglobulin G in Primary Immunodeficiency Diseases.
Li Z; Follman K; Freshwater E; Engler F; Yel L
J Clin Immunol; 2023 Nov; 43(8):2127-2135. PubMed ID: 37773562
[TBL] [Abstract][Full Text] [Related]
3. Differences in Patient Demographics and Healthcare Costs of Patients with PIDD Receiving Intravenous or Subcutaneous Immunoglobulin Therapies in the United States.
Runken MC; Noone JM; Blanchette CM; Zacherle E; Howden R
Am Health Drug Benefits; 2019 Oct; 12(6):294-304. PubMed ID: 31908713
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous immunoglobulin therapy for adult patients with primary immunodeficiency disease: Qatar experience.
Thalappil S; Khalil S; Hassini S; Al-Nesf M
Qatar Med J; 2023; 2023(2):3. PubMed ID: 38025333
[TBL] [Abstract][Full Text] [Related]
5. Calculating the dose of subcutaneous immunoglobulin for primary immunodeficiency disease in patients switched from intravenous to subcutaneous immunoglobulin without the use of a dose-adjustment coefficient.
Fadeyi M; Tran T
P T; 2013 Dec; 38(12):768-70. PubMed ID: 24391400
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: A Historical Perspective.
Cocito D; Peci E; Torrieri MC; Clerico M
J Clin Med; 2023 Nov; 12(22):. PubMed ID: 38002576
[TBL] [Abstract][Full Text] [Related]
7. A systematic review of the cost and cost-effectiveness of immunoglobulin treatment in patients with hematological malignancies.
Carrillo de Albornoz S; Chai KL; Higgins AM; Petrie D; Wood EM; McQuilten ZK
Int J Technol Assess Health Care; 2024 May; 40(1):e32. PubMed ID: 38751245
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous immunoglobulins (SCIG) for chronic inflammatory demyelinating polyneuropathy (CIDP): A comprehensive systematic review of clinical studies and meta-analysis.
Ramzi A; Maya S; Balousha N; Sabet H; Samir A; Roshdy MR; Aljarrah G; Saleh S; Kertam A; Serag I; Shiha MR
Neurol Sci; 2024 Jun; ():. PubMed ID: 38937399
[TBL] [Abstract][Full Text] [Related]
9. 7th International Immunoglobulin Conference: Neurology.
Nobile-Orazio E; Lewis RA
Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):22-4. PubMed ID: 25546749
[TBL] [Abstract][Full Text] [Related]
10. Long-term day-case treatment of peripheral neuromuscular disease with intravenous immunoglobulin: the practice of a regional day-case service in Preston, Lancashire.
Nixon J; McHugh C; Jones S
Clin Med (Lond); 2013 Aug; 13(4):358-61. PubMed ID: 23908504
[TBL] [Abstract][Full Text] [Related]
11. The Experiences of Children with Primary Immunodeficiency Who Receive Immunoglobulin Subcutaneously Instead of Intravenously.
Köse S; Sabetsarvestani R; Geçkil E; Kaleci E; Dönmez H
J Pediatr Health Care; 2024; 38(1):13-20. PubMed ID: 37702646
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease.
Skoda-Smith S; Torgerson TR; Ochs HD
Ther Clin Risk Manag; 2010 Feb; 6():1-10. PubMed ID: 20169031
[TBL] [Abstract][Full Text] [Related]
13. [Altered antibody titers in patients with neuromuscular diseases after high-dose intravenous immunoglobulin therapy].
Shiraishi W; Inamori Y; Matsuyoshi A; Hashimoto T
Rinsho Shinkeigaku; 2024 Mar; 64(3):157-162. PubMed ID: 38369330
[TBL] [Abstract][Full Text] [Related]
14. Immunoglobulin utilization in Canada: a comparative analysis of provincial guidelines and a scoping review of the literature.
Harmon M; Riazi K; Callum J; Arnold DM; Barty R; Sidhu D; Heddle NM; MacLeod L; Li N
Allergy Asthma Clin Immunol; 2023 Sep; 19(1):85. PubMed ID: 37717038
[TBL] [Abstract][Full Text] [Related]
15. Hyaluronidase-Facilitated High-Dose Subcutaneous IgG Effectively Controls Parvovirus B19 Infection in a Pediatric Cardiac Transplant Patient With Severe T-Cell Lymphopenia.
Cruz RJ; Dasso JF; Duff C; Krasnopero D; Long Z; Ellison M; Nieves D; Sriaroon P; Asante-Korang A; Walter JE
Open Forum Infect Dis; 2020 May; 7(5):ofaa076. PubMed ID: 32391400
[TBL] [Abstract][Full Text] [Related]
16. Development, implementation and impact of an immunoglobulin stewardship programme in Saskatchewan, Canada.
Sarker K; Vanstone JR; Adigun O; Boutilier B; Comeau J; Degelman ML; Gottselig P; Berry WE; Milne A; Van Vliet P; Harding SR
Vox Sang; 2024 Apr; 119(4):335-343. PubMed ID: 38229560
[TBL] [Abstract][Full Text] [Related]
17. The development and implementation of a subcutaneous immunoglobulin (SCIG) program at CancerCare Manitoba.
Streu E
Can Oncol Nurs J; 2016; 26(2):137-144. PubMed ID: 31148713
[No Abstract] [Full Text] [Related]
18. IVIG and Small Fiber Neuropathy: The Ongoing Search for Evidence.
Gibbons CH; Klein C
Neurology; 2021 May; 96(20):929-930. PubMed ID: 33766998
[No Abstract] [Full Text] [Related]
19. Emerging Therapies in Immune Thrombocytopenia.
Audia S; Bonnotte B
J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33801294
[TBL] [Abstract][Full Text] [Related]
20. Correct identification of incomplete Kawasaki disease.
Li T; Feng J; Li N; Liu T
J Int Med Res; 2021 Mar; 49(3):3000605211001712. PubMed ID: 33784852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
